Genentech, Inc.
1 DNA Way
South San Francisco
California
94080-4990
United States
Tel: 650-225-1000
Fax: 650-225-6000
Website: http://www.gene.com/
About Genentech, Inc.
Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 40 years. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. We are among the world's leading biotech companies, with multiple products on the market and a promising development pipeline. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
Connect with us!
Being a scientist at Genentech means being a drug discoverer. Mike Varney, head of Genentech Research and Early Development, explains how this culture of innovation is helping to solve some of the hardest biomedical problems of our time.
1172 articles with Genentech, Inc.
-
When the U.S. Food and Drug Administration approved Genentech’s Xofluza, a single-dose treatment for the flu, it was met with great fanfare, particularly in Japan, where the treatment was first discovered.
-
Every year, BioSpace analyzes the biotech industry, looking for the hot new biotech startups to watch. Here’s a look at the top 3 companies from the Top 20 Life Science Startups to Watch in the U.S. from 2016.
-
Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech
2/5/2019
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune disease, asthma and allergic disease, and cancer, today announced it has entered into a research and license agreement with Genentech
-
Genentech, a Roche company, is flexing its litigation muscle this week. The South San Francisco-based company has filed 18 lawsuits over the past few weeks to block competitors from selling a generic version of a treatment for idiopathic pulmonary fibrosis, a fatal lung-scarring disease.
-
Genentech to Discontinue Phase III CREAD 1 and 2 Clinical Studies of Crenezumab in Early Alzheimer’s Disease (AD) - Other Company Programs in AD Continue
1/30/2019
Genentech, a member of the Roche Group, announced the decision to discontinue CREAD 1 and CREAD 2 Phase III studies of the investigational anti-beta-amyloid molecule crenezumab in people with early sporadic Alzheimer’s disease.
-
First Patient Enrolled in Pivotal Study of RG6042 (IONIS-HTT Rx) for People with Huntington's Disease
1/28/2019
First of 4+ Ionis programs expected to advance to pivotal studies this year
-
BioSpace Movers and Shakers: Jan. 25
1/25/2019
Movers and Shakers is BioSpace's weekly roundup of leadership appointments and changes within the biopharma world. Included this week are Genentech, Editas, Sage, Sangamo, and more. -
After Bill Anderson moved from the role of Genentech chief executive officer to helm parent company Roche’s division Roche Pharmaceuticals earlier this month, the South San Francisco-based subsidiary has operated without a top executive – until now.
-
Amgen and Allergan announced positive top-line results from a Phase I/Phase III trial of their biosimilar candidate, ABP 798, to Genentech and Biogen’s Rituxan (rituximab).
-
The U.S. Food and Drug Administration (FDA) approved South Korea’s Samsung Bioepis’ Ontruzant (trastuzumab-dttb), a biosimilar to Genentech’s Herceptin (trastuzumab).
-
FDA Accepts Genentech’s Supplemental Biologics License Application for Tecentriq Plus Chemotherapy (Abraxane and Carboplatin) for the Initial Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
1/17/2019
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Tecentriq® in combination with Abraxane® and carboplatin for the initial (first-line) treatment of people with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR or ALK genomic tumor aberrations.
-
The U.S. government has been pushing to increase access to experimental drugs over the last two years. On August 18, 2018, the RACE for Children Act was signed into law as part of the 2017 FDA Reauthorization Act, which amended the Pediatric Research Equity Act (PREA).
-
PhRMA Welcomes Genentech and Gilead Sciences to Association
1/17/2019
The Pharmaceutical Research and Manufacturers of America (PhRMA) announced today that Genentech, a member of the Roche Group, South San Francisco, and Gilead Sciences, Inc., Foster City, California joined the association as members.
-
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
-
According to U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb, less than two percent of Americans use biologics, but they account for 40 percent of total spending on prescription drugs.
-
With more than 82,500 employees working in the sector, California’s Bay Area is one of the strongest homes for biotech companies in the world.
-
Adaptive Biotechnologies and Genentech Launch Personalized Cancer-Care Program Worth $2 Billion+
1/7/2019
Seattle-based Adaptive Biotechnologies forged a collaboration with Genentech that could be worth up to $2 billion to develop and commercialize novel neoantigen directed T-cell therapies for the individualized treatment of a broad range of cancers. -
Adaptive Biotechnologies to Enter into Worldwide Collaboration and License Agreement with Genentech to Develop Personalized Cellular Therapies for the Treatment of Cancer
1/4/2019
Adaptive Biotechnologies, an immune-driven medicine company, today announced that it will enter into a worldwide collaboration and license agreement with Genentech,
-
Traditionally, Genentech has tended to operate with less hands-on scrutiny from the business bean counters at its Swiss Roche headquarters. These more recent job cuts suggest those days may be over.
-
Readers' Picks: Top 10 Stories of 2018
12/28/2018
As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.